Atorvastatin 40 Mg Tablet

Atorvastatin 40mg is indidacted to reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD.

Take the it at the same time each day. Swallow the tablet whole. Do not break, crush, or chew it. Take this medicine with or without food. Do not drink large amounts of alcohol with atorvastatin. This could cause unwanted effects on the liver.

Store at a controlled room temperature between 20 and 25 degrees C

Adverse effects may include: nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection Side effects may include diarrhea, UTIs, extremity pain, nasopharyngitis, and arthralgia.

Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels • Hypersensitivity to any component of this medication (4). • Pregnancy . • Lactation

Use under medical supervision. Regular monitoring of lipid profile and liver function tests may be required. Inform your doctor immediately if you experience unexplained muscle pain, tenderness, or weakness. Avoid excessive alcohol consumption. Maintain healthy dietary habits and regular exercise. Keep out of reach of children.

Product Information: LIPITOR(R) oral tablets, atorvastatin calcium oral tablets. Parke-Davis (Per FDA), New York, NY, 2014 Product Information: Atorvastatin Uxa oral tablet, atorvastatin calcium trihydrate oral tablet. Uxa Farma SA (per AEMPS;Spain), Avda. San Francisco Javier 24, 41018 Seville, Spain, 2019.

Atorvastatin calcium selectively and competitively inhibits HMG-CoA reductase, a rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a sterol and cholesterol precursor Triglycerides and cholesterol are incorporated into very low density lipoproteins (VLDL) in the liver and are released into plasma for distribution to peripheral tissues. Low-density lipoproteins (LDL) are formed from VLDL and are catabolized primarily through the receptor with high affinity for LDL receptor. Atorvastatin reduces plasma cholesterol and lipoprotein concentrations by inhibiting HMG-CoA reductase and subsequent hepatic cholesterol biosynthesis in the liver and increasing the number of liver receptors for LDL on the cell surface, leading to increased absorption and catabolism of LDL. Atorvastatin reduces LDL production and produces a profound and sustained increase in LDL receptor activity along with a beneficial change in the quality of circulating LDL.

Cardiovascular Risk Reduction Agent Antihyperlipidemic Lipid-Lowering Agent